# Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 8-K

CUMBERLAND PHARMACEUTICALS INC

Form 8-K

November 23, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934			
Date of Report (Date of Earliest Event Reported):		November 23, 2015 (November 23, 2015)	
Cumberland Pharmaceuticals Inc.			
(Exact name of registrant as specified in its charter)			
Tennessee	001-33637		62-1765329
(State or other jurisdiction of incorporation)	(Commission File Number	er)	(I.R.S. Employer Identification No.)
2525 West End Avenue, Suite 950, Nashville, Tennessee			37203
(Address of principal executive offices)			(Zip Code)
Registrant's telephone number, including area code: (615) 255-0068 Not Applicable			
Former name or former address, if changed since last report			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

## Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 8-K

#### Item 8.01 Other Events

On November 23, 2015, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the approval of Caldolor<sup>®</sup> (ibuprofen) Injection for pediatric patients six months of age and older. A copy of the press release is furnished as Exhibit 99.1.

### Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

November 23, 2015 By: A.J. Kazimi

Name: A.J. Kazimi

Title: Chief Executive Officer

**Exhibit Index** 

Exhibit No. Description

99.1 Press release dated November 23, 2015